AS 35

Drug Profile

AS 35

Latest Information Update: 03 Feb 2004

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics
  • Mechanism of Action Leukotriene receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 31 Dec 2001 Discontinued - Phase-II for Asthma in Japan (Inhalation)
  • 31 Dec 2001 Discontinued - Phase-II for Asthma in Japan (PO)
  • 19 Oct 2001 No-Development-Reported for Asthma in Japan (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top